SHAPING THE FUTURE OF DIGITAL DIABETES CARE: MELISSA AT ATTD 2025
A few weeks ago, experts from academia, clinicians, and industry professionals came together in Amsterdam and Online for the 18th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2025). Recognized as the ultimate platform for innovation in diabetes care, ATTD showcased the latest global advancements in research, technology, and treatment—including cutting-edge devices and digital health solutions. The MELISSA project was proudly represented at ATTD 2025 with three scientific posters and strong attendance from many consortium partners.
Take a look at the posters by clicking on the titles.
Diabetes apps are already everywhere; however, few have solid clinical evidence even though they influence medical decisions while not being regulated as medical devices. Under the title "Systematic Review of the Literature on Diabetes-related Mobile Apps, a Mixed Methods Approach" our partner National & Kapodistrian Univerity of Athens (NKUA) presented a poster which highlighted that AI-enabled and high-risk apps should undergo rigorous clinical evaluation to ensure patient safety. We in MELISSA firmly believe that apps must be safe, effective and clinically validated. With our upcoming clinical trials we are also contributing to the growing evidence behind digital and AI-based tools for diabetes care.
The University of Bern (UBERN) presented a poster titled “Personalised Diabetes Self-Management with Reinforcement Learning: An In-Silico Validation for Insulin-Treated Individuals,” showcasing the performance of the self-learning ABBA algorithm, which powers the MELISSA app. While the study focused on in-silico validation, it highlighted the algorithm’s ability to adapt insulin therapy for both type 1 and insulin-treated type 2 diabetes. This represents one of the largest validations of a self-learning approach in diabetes care, ahead of MELISSA’s upcoming multi-country clinical trial.
Finally, Maastricht University (UM) gave insights into our upcoming clinical trial with a poster titled "Study protocol for the MobilE artificial Intelligence Solution for diabeteS Adapted Care - MELISSA trial". The poster highlighted MELISSA’s potential to improve glycaemic control and support people with diabetes in their self-management by providing AI-driven individualised insulin dose suggestions, independent of currently available diabetes management devices.
About ATTD
The core objective of ATTD is to spotlight pioneering technologies and therapies for diabetes management, fostering collaboration among technology developers, diabetes care professionals, researchers, industries, startups, investors, regulatory bodies, and individuals living with diabetes. Every year professionals from around the globe convene to exchange insights and disseminate the latest advancements in the field of diabetes research and technologies.
